SAN JOSE, Calif., July 25, 2016 /PRNewswire/ -- ProTrials Research, Inc., a leader in the clinical research organization
"We are extremely pleased that Calithera has selected ProTrials to support research into CB-839," said Jodi Andrews, Co-Founder and Co-CEO of ProTrials. "We recognize the potential of CB-839 to become an important therapeutic agent for the treatment of cancer, and look forward to applying our expertise to support Calithera's development of this first-in-class investigational compound."
Calithera's CB-839 program is currently in Phase 1b clinical studies. Phase 1 data presented in June at the 2016 American Society of Clinical Oncology (ASCO) meeting in Chicago demonstrated the clinical activity, tolerability, and unique mechanism of action of CB-839 in patients with renal cell carcinoma (RCC) and triple negative breast cancer (TNBC).
"ProTrials and Calithera share a commitment to high quality research and clinical innovation," said Susan Molineaux, PhD, President and Chief Executive Officer of Calithera. "Given their reputation for clinical research excellence, we are pleased to engage ProTrials to support the advancement of CB-839."
To learn more about the suite of clinical research services offered by ProTrials, please visit www.protrials.com.
About ProTrials Research, Inc.
Founded in 1996, ProTrials Research, Inc. is a clinical research organization (CRO) headquartered in San Jose, CA, with clinical operations personnel located throughout North America and worldwide. The company works with clients in the pharmaceutical, biotechnology and medical device industries, providing high quality study management, site monitoring, project management and associated clinical operations services. ProTrials Global Limited, the company's UK-based subsidiary, supports European-based clinical activities. ProTrials also has international partners that offer local support in countries throughout Asia, Latin America and Australia. For more information or to discuss your clinical research needs, please visit www.protrials.com or call 650.864.9195.
Press Contact: Wendy Powers ProTrials Research, Inc. 650.864.9195 Email
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/protrials-research-inc-selected-by-calithera-biosciences-inc-for-early-phase-clinical-trial-support-300303176.html
SOURCE ProTrials Research, Inc.
Subscribe to our Free Newsletters!
Urinary retention is a condition where a person is unable to voluntarily empty the urinary bladder ...
Hashimoto's thyroiditis is an autoimmune disorder of the thyroid causing hypothyroidism. Synthetic ...
Strokes occur when blood flow to an area of the brain is cut off. It is imperitive to detect the ...View All